Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP308258.RAormQUyRMeVg_YhP6kLbUqEG02rhQM3s9HKUrNRyn3wQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP308258.RAormQUyRMeVg_YhP6kLbUqEG02rhQM3s9HKUrNRyn3wQ130_assertion type Assertion NP308258.RAormQUyRMeVg_YhP6kLbUqEG02rhQM3s9HKUrNRyn3wQ130_head.
- NP308258.RAormQUyRMeVg_YhP6kLbUqEG02rhQM3s9HKUrNRyn3wQ130_assertion description "[Although previous attempts to target therapy to colorectal cancer using the carcinoembryonic antigen (CEA) promoter have demonstrated specificity, this has been achieved at the cost of 10- to 300-fold loss in activity compared with strong but nonspecific rous sarcoma virus (RSV) or cytomegalovirus promoters.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308258.RAormQUyRMeVg_YhP6kLbUqEG02rhQM3s9HKUrNRyn3wQ130_provenance.
- NP308258.RAormQUyRMeVg_YhP6kLbUqEG02rhQM3s9HKUrNRyn3wQ130_assertion evidence source_evidence_literature NP308258.RAormQUyRMeVg_YhP6kLbUqEG02rhQM3s9HKUrNRyn3wQ130_provenance.
- NP308258.RAormQUyRMeVg_YhP6kLbUqEG02rhQM3s9HKUrNRyn3wQ130_assertion SIO_000772 11956093 NP308258.RAormQUyRMeVg_YhP6kLbUqEG02rhQM3s9HKUrNRyn3wQ130_provenance.
- NP308258.RAormQUyRMeVg_YhP6kLbUqEG02rhQM3s9HKUrNRyn3wQ130_assertion wasDerivedFrom befree-20140225 NP308258.RAormQUyRMeVg_YhP6kLbUqEG02rhQM3s9HKUrNRyn3wQ130_provenance.
- NP308258.RAormQUyRMeVg_YhP6kLbUqEG02rhQM3s9HKUrNRyn3wQ130_assertion wasGeneratedBy ECO_0000203 NP308258.RAormQUyRMeVg_YhP6kLbUqEG02rhQM3s9HKUrNRyn3wQ130_provenance.